QCZ484 Phase 2 Extension Trial for Hypertensive Patients

The NIH has registered a new Phase 2 open-label extension study (NCT07543120) for the investigational drug QCZ484 in hypertensive patients. The study will enroll patients who previously completed the parent study CQCZ484A12201 or other QCZ484 protocols. The sole intervention is QCZ484.

Pharmaceutical companies sponsoring QCZ484 development should ensure trial sites are aware of the extension protocol and enrollment criteria. Clinical investigators at participating sites should review the parent study completion requirements and verify eligibility criteria before enrolling patients in the extension.